the use of dexmedetomidine as an analgesic after uvulopalatopharyngoplasty for obstructive sleep apnea.

analgesic and sedative properties of dexmedetomidine infusion after uvulopalatopharyngoplasty for obstructive sleep apnea.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000731291

Enrollment

Registered

2009-08-25

Start date

2007-07-11

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Dexmedetomidine is an alpha2- adrenergic agonist with sedative and analgesic properties. This study aimed to investigate if the use of continuous dexmedetomidine infusion with i.v. morphine patient-controlled analgesia (PCA) could improve postoperative analgesia while reducing opioid consumption and opioid-related side effects.

Interventions

dexmedetomidine loading dose:1 microgram /kg.intravenous infusion over 20min;this was administered 30 min before the suspected end of surgery infusion dose:0.6 microgram /kg / h.following the loading infusion and continued till the end of the first postoperative day

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

38 Years to 55 Years

Healthy volunteers

Inclusion criteria

-frequent loud snoring and arousal from sleep. -apnea-hypopnea index 20-40.

Exclusion criteria

-history of ischemic heart disease. -long term use of certain medications(beta blockers, sedative and analgesics).

Outcome results